美国第13株耐万古霉素金黄色葡萄球菌分离株报告。
Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States.
作者信息
Limbago Brandi M, Kallen Alexander J, Zhu Wenming, Eggers Paula, McDougal Linda K, Albrecht Valerie S
机构信息
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
出版信息
J Clin Microbiol. 2014 Mar;52(3):998-1002. doi: 10.1128/JCM.02187-13. Epub 2013 Dec 26.
Abstract
Vancomycin-resistant Staphylococcus aureus (VRSA), an important multidrug-resistant organism of public health concern, has been infrequently identified in the United States since 2002. All previous VRSA isolates belonged to clonal complex 5, a lineage associated primarily with health care. This report describes the most recent (13th) U.S. VRSA isolate, the first to be community associated.
摘要
耐万古霉素金黄色葡萄球菌（VRSA）是一种引起公共卫生关注的重要多重耐药菌，自2002年以来在美国很少被发现。此前所有VRSA分离株都属于克隆复合体5，这是一个主要与医疗保健相关的谱系。本报告描述了美国最新的（第13株）VRSA分离株，这是首例与社区相关的分离株。
相似文献
1
Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States.
J Clin Microbiol. 2014 Mar;52(3):998-1002. doi: 10.1128/JCM.02187-13. Epub 2013 Dec 26.
2
Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit.
J Clin Microbiol. 2008 Jul;46(7):2345-52. doi: 10.1128/JCM.00154-08. Epub 2008 May 28.
3
In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Int J Antimicrob Agents. 2010 Jul;36(1):69-72. doi: 10.1016/j.ijantimicag.2010.02.023. Epub 2010 Apr 21.
4
Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007.
Emerg Infect Dis. 2009 Jun;15(6):943-5. doi: 10.3201/eid1506.081312.
5
Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with Methicillin-resistant S. aureus hospital-acquired infection in the United States.
mBio. 2012 May 22;3(3). doi: 10.1128/mBio.00112-12. Print 2012.
6
Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.
Clin Infect Dis. 2008 Mar 1;46(5):668-74. doi: 10.1086/527392.
7
In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Int J Antimicrob Agents. 2010 Nov;36(5):478-80. doi: 10.1016/j.ijantimicag.2010.07.016. Epub 2010 Sep 16.
8
In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates.
Clin Infect Dis. 2012 Aug;55(4):582-6. doi: 10.1093/cid/cis492. Epub 2012 May 21.
9
Molecular analysis of community-acquired methicillin-susceptible and resistant Staphylococcus aureus isolates recovered from bacteraemic and osteomyelitis infections in children from Tunisia.
Clin Microbiol Infect. 2011 Jul;17(7):1020-6. doi: 10.1111/j.1469-0691.2010.03367.x. Epub 2010 Oct 26.
10
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
J Antimicrob Chemother. 2009 Aug;64(2):364-9. doi: 10.1093/jac/dkp176. Epub 2009 May 19.
引用本文的文献
1
Identification and Characterization of Vancomycin-Resistant Staphylococcus aureus CC45/USA600, North Carolina, USA, 2021.
Emerg Infect Dis. 2025 Jan;31(1):194-196. doi: 10.3201/eid3101.241573.
2
Pathogenicity potential of enterococci isolated from a Veterinary Biological Isolation and Containment Unit.
Front Vet Sci. 2024 Oct 21;11:1458069. doi: 10.3389/fvets.2024.1458069. eCollection 2024.
3
ST105 Lineage of MRSA: An Emerging Implication for Bloodstream Infection in the American and European Continents.
Antibiotics (Basel). 2024 Sep 18;13(9):893. doi: 10.3390/antibiotics13090893.
4
Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin's clinical durability.
PLoS Pathog. 2024 Aug 29;20(8):e1012422. doi: 10.1371/journal.ppat.1012422. eCollection 2024 Aug.
5
The wound microbiota: microbial mechanisms of impaired wound healing and infection.
Nat Rev Microbiol. 2024 Aug;22(8):507-521. doi: 10.1038/s41579-024-01035-z. Epub 2024 Apr 4.
6
A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.
Antibiotics (Basel). 2023 Sep 28;12(10):1492. doi: 10.3390/antibiotics12101492.
7
Synthesis of vancomycin fluorescent probes that retain antimicrobial activity, identify Gram-positive bacteria, and detect Gram-negative outer membrane damage.
Commun Biol. 2023 Apr 14;6(1):409. doi: 10.1038/s42003-023-04745-x.
8
Genomic Analysis of Vancomycin-Resistant Staphylococcus aureus Isolates from the 3rd Case Identified in the United States Reveals Chromosomal Integration of the Locus.
Microbiol Spectr. 2023 Mar 28;11(2):e0431722. doi: 10.1128/spectrum.04317-22.
9
Nanomedicine: New Frontiers in Fighting Microbial Infections.
Nanomaterials (Basel). 2023 Jan 25;13(3):483. doi: 10.3390/nano13030483.
10
Molecular Mechanisms of Drug Resistance in .
Int J Mol Sci. 2022 Jul 22;23(15):8088. doi: 10.3390/ijms23158088.
本文引用的文献
1
Prevalence and risk factors associated with vancomycin-resistant Staphylococcus aureus precursor organism colonization among patients with chronic lower-extremity wounds in Southeastern Michigan.
Infect Control Hosp Epidemiol. 2013 Sep;34(9):954-60. doi: 10.1086/671735. Epub 2013 Jul 26.
2
Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains.
Int J Antimicrob Agents. 2013 Oct;42(4):370-1. doi: 10.1016/j.ijantimicag.2013.06.004. Epub 2013 Jul 21.
3
First case of infection with vancomycin-resistant Staphylococcus aureus in Europe.
Lancet. 2013 Jul 20;382(9888):205. doi: 10.1016/S0140-6736(13)61219-2. Epub 2013 Jun 21.
4
pSK41-like plasmid is necessary for Inc18-like vanA plasmid transfer from Enterococcus faecalis to Staphylococcus aureus in vitro.
Antimicrob Agents Chemother. 2013 Jan;57(1):212-9. doi: 10.1128/AAC.01587-12. Epub 2012 Oct 22.
5
Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with Methicillin-resistant S. aureus hospital-acquired infection in the United States.
mBio. 2012 May 22;3(3). doi: 10.1128/mBio.00112-12. Print 2012.
6
Evaluation of the impact of direct plating, broth enrichment, and specimen source on recovery and diversity of methicillin-resistant Staphylococcus aureus isolates among HIV-infected outpatients.
J Clin Microbiol. 2011 Dec;49(12):4126-30. doi: 10.1128/JCM.05323-11. Epub 2011 Oct 12.
7
Dissemination of an Enterococcus Inc18-Like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2010 Oct;54(10):4314-20. doi: 10.1128/AAC.00185-10. Epub 2010 Jul 26.
8
Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States.
Antimicrob Agents Chemother. 2010 Sep;54(9):3804-11. doi: 10.1128/AAC.00351-10. Epub 2010 Jun 28.
9
Methicillin-resistant Staphylococcus aureus in horses and horse personnel: an investigation of several outbreaks.
Vet Microbiol. 2010 Feb 24;141(1-2):96-102. doi: 10.1016/j.vetmic.2009.08.009. Epub 2009 Aug 8.
10
Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis.
J Clin Microbiol. 2009 May;47(5):1344-51. doi: 10.1128/JCM.02264-08. Epub 2009 Mar 25.
Zotero 插件